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a  b  s  t  r  a  c  t
INTRODUCTION:  Splenic  metastasis  of gallbladder  carcinoma  is extremely  rare. Speciﬁc  anatomical,  histo-
logical,  and functional  properties  of spleen  are believed  to be  responsible  for the  rarity  of solitary  splenic
metastasis.
PRESENTATION  OF  CASE:  We  present  the  case  of a 62-year-old  female  who  developed  metachronous
splenic  metastasis  of  adenosquamous  carcinoma  of the  gallbladder.  We  performed  central  bisegmen-
tectomy  of  the  liver  for gallbladder  carcinoma.  The  patient  subsequently  presented  3 months  later  with
isolated  splenic  metastasis  and  liver  metastasis.  Splenectomy  and  partial  hepatectomy  was  performed  at
this  time.  Histological  examination  conﬁrmed  metastatic  adenosquamous  carcinoma  of  the  gallbladder.
No signs  of recurrence  were  observed  at 3 months  after  the  second  surgery.
DISCUSSION:  Although  splenectomy  provides  a  potential  means  of  radical  treatment  in patients  with
isolated  splenic  metastases,  it should  be  performed  with  caution  as  splenic  metastatic  lesions may  rep-
resent the initial  clinical  manifestation  of  systemic  metastases  at multiple  sites.  In  this  case,  radical
surgery  was  performed  following  the  conﬁrmation  of  no new  unresectable  metastatic  lesions  or systemic
dissemination.
CONCLUSION:  This  is the ﬁrst  report  on  the  adenosquamous  splenic  metastasis  from  the  gallbladder
carcinoma.  Curative  resection  may  be the  treatment  of  choice  for  prolonging  survival  in  patients  with
the  splenic  metastasis  of gallbladder  carcinoma.
Publi
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. Introduction
Splenic metastases are rare, comprising 0.96% of reported cases
f metastatic cancer [1]. Speciﬁc anatomical, histological, and func-
ional properties of the spleen are believed to be responsible for
he rarity of solitary splenic metastasis. As majority of splenic
etastases are detected concurrently with multi-organ metastases,
solated splenic metastasis is extremely rare. Gallbladder (GB) car-
inoma commonly metastasizes to the liver and regional lymph
odes and rarely the spleen. Adenosquamous carcinoma of GB is
 relatively rare (<10%) type of gallbladder carcinoma, deﬁned as
eing comprised of 25–99% squamous cells [2,3].
Abbreviations: GB, gallbladder; CT, computed tomography; MRI, magnetic reso-
ance imaging; FDG-PET, ﬂuorodeoxyglucose positron emission tomography; SSC,
quamous cell carcinoma antigen.
∗ Corresponding author at: Iwakuni Clinical Center, Department of Surgery, 1-1-
Atago-machi, Iwakuni-shi, Yamaguchi 740-8510, Japan. Fax: +81 827 35 5600.
E-mail address: masashi11232001@yahoo.co.jp (M. Utsumi).
ttp://dx.doi.org/10.1016/j.ijscr.2016.01.032
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/).shed  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
 BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
In this study, we report a case of splenic metastasis of
adenosquamous carcinoma of GB occurring 3 months after initial
curative treatment which was treated by splenectomy.
2. Presentation of case
We report the case of a 62-year-old female who  presented with
right hypochondralgia and was subsequently diagnosed with gall-
bladder cancer by abdominal ultrasonography before referral to our
hospital for possible surgery. Computed tomography (CT) revealed
an irregular gallbladder mass involving the liver (Fig. 1). A pre-
operative diagnosis of stage T3N0M0 gallbladder carcinoma was
made according to the UICC classiﬁcation [4]. Serum levels of tumor
biomarkers, including carcinoembryonic antigen and carbohydrate
antigen 19-9 (CA19-9), were within the normal limits. However,
squamous cell carcinoma antigen (SCC) was higher than the normal
range (6.5 ng/ml; reference values, 0–1.5 ng/ml). Central bisegmen-
tectomy of the liver with partial resection of transverse colon, as
performed as laparotomy, revealed liver metastasis in segment 8
and invasion into the transverse colon. Lymph node dissection at
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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wig. 1. Abdominal computed tomography reveal the gallbladder carcinoma.
A) The axial view of contrast-enhanced CT. (B) The coronal view of contrast-enhan
ow  density irregular mass within the gallbladder. The mass was  diagnosed as gallb
he hepatoduodenal ligament and along the common hepatic artery
as also performed.
Macroscopically, the GB tumor was 8.0 cm in size with mas-
ive invasion into the liver and transverse colon. Histopathological
xamination of the specimen demonstrated adenosquamous car-
inoma with liver metastases in segment 8 and lymph node
etastases along the common bile duct. Therefore, the ﬁnal patho-
ogical stage was determined as pT4N1M1, pStage IV, according
o the UICC system [4]. Serum SCC levels decreased to 0.6 ng/ml
uring the early postoperative period. Two courses of adjuvant
hemotherapy consisting of TS-1 80 mg/day for 14 days were
dministered with a 7-day interval.
Three months after initial surgery, serum SCC levels elevated to
.7 ng/ml. Enhanced CT imaging revealed a low density mass in the
pleen (Fig. 2A). Fluorodeoxyglucose positron emission tomogra-
hy (FDG-PET) demonstrated abnormal FDG accumulation in the
pleen (Fig. 2B). Other remote organ metastases were not observed
n either CT or FDG-PET imaging. The previous history of GB car-
inoma contributed to a presumptive diagnosis of metachronous
solated splenic metastases.
Two courses of intravenous chemotherapy consisting of gem-
itabine (1200 mg)  and cisplatin (30 mg)/day were administrated
ue to early metastasis after the initial surgery. However, serum
CC levels gradually increased to 65.8 ng/ml. Five months after the
nitial surgery, CT imaging revealed an enlarging splenic tumor and
ew liver metastasis in segment 6, indicating a poor response to
hemotherapy (Fig. 2C). No other intra-abdominal organ metas-
ases or peritoneal dissemination were observed at this time.
herefore, splenectomy and partial liver resection were performed
or the treatment of splenic and liver metastases. Upon laparotomy,
ntraoperative lavage cytology was negative and no recurrence of
odular masses was observed except in the spleen and liver. As
he splenic tumor had invaded into the left diaphragm, combined
artial resection of the left diaphragm was performed.
Macroscopically, the splenic tumor was solitary and homo-
eneuous. The cut surface of the resected specimen revealed
 whitish splenic mass with a diameter of 6.7 cm (Fig. 3).
istopathologically, the splenic and liver tumors were found to
e adenosquamous carcinoma, consistent with metastasis of the
rimary GB carcinoma (Fig. 4). The postoperative course was
neventful. SCC levels decreased to within normal limits. The
atient was discharged on postoperative day 13. Chemotherapy
onsisting of TS-1 or gemcitabine and cisplatin was not effective.
herefore, we administered adjuvant chemotherapy consisting of
ocetaxel and nedaplatin, which we expected to be effective. There
as no sign of recurrence at 3 months after the second surgery.T. Contrast-enhanced CT demonstrating increased gallbladder wall thickness and a
r cancer with invasion into the liver (arrows).
3. Discussion
Splenic metastases from non-hematologic malignancies
account for only 0.96% of the metastatic carcinoma and 2.9–4.4%
of the autopsied carcinoma specimens [5,6]. In majority of cases,
the spleen is involved as a part of diffuse carcinomatosis with
the presence of splenic metastases usually indicating widespread
tumor dissemination [7,8]. Very few splenic metastases are
observed as isolated splenic lesions, synchronous or metachronous
to the primary tumor. There have been few case reports and
reviews of isolated splenic metastases from carcinoma of the
colorectum, stomach, kidney, or ovary [9–14]. Splenic metastasis
from GB cancer is extremely rare. Taki et al. ﬁrst reported isolated
splenic metastasis from adenocarcinoma of GB [15]. Therefore,
this presents the second reported case of the splenic metastasis
of GB successfully treated by surgical resection. According to
histopathological diagnosis, to the best of our knowledge, this is
the ﬁrst report of splenic metastasis of adenosquamous cancer of
the gallbladder.
The rarity of splenic metastases is believed to be due mechan-
ical factors and the splenic microenvironment [16]. Mechanical
factors related to the spleen, such as constant blood ﬂow through
the spleen, rhythmic contraction of the splenic capsule, the sharp
angle of the splenic artery after branching from the celiac trunk,
and the lack of afferent lymphatic vessels, may  protect against
tumor cells inﬁltration and the development of metastases [17].
Further, the splenic microenvironment may  inhibit cancer cell pro-
liferation [17,18]. Although the precise mechanisms underlying the
inhibition of cancer cell growth has yet to be fully elucidated, the
immunological environment of the spleen may  be particularly hos-
tile to tumor cells.
Adenosquamous carcinoma of GB is a relatively rare type of gall-
bladder carcinoma associated with worse prognosis. Primary GB
carcinoma includes the following histological types in a decreasing
order of incidence: adenocarcinoma, adenosquamous carcinoma,
squamous cell carcinoma, and oat cell carcinoma [19]. In GB
carcinoma, tumor stages of adenosquamous and squamous cell
carcinoma are signiﬁcantly advanced at presentation, compared
to adenocarcinoma [3,20,21]. The overall prognosis of adenosqua-
mous GB carcinoma appears to be worse, with most patients dying
within few months of diagnosis [2]. However, curative surgical
resection of adenosquamous or squamous cell carcinoma might
result in disesase-free survival rates comparable to those for ade-
nocarcinoma [3,20,21].A metastatic origin should be suspected for all isolated splenic
tumors found during oncologic follow-up. Serum tumor marker
levels reportedly have predictive value in detecting isolated splenic
CASE  REPORT  –  OPEN  ACCESS
M. Utsumi et al. / International Journal of Surgery Case Reports 20 (2016) 109–113 111
Fig. 2. Abdominal computed tomography and PET-CT reval a splenic tumor.
(A)  Contrast-enhanced CT demonstrating a 4-cm low density splenic mass (arrow) considered to represent splenic metastasis 3 months after initial surgery. (B) PET-CT
demonstrated uptake of FDG in the spleen. No other intra-abdominal organ metastases or peritoneal dissemination were observed. The mass was  diagnosed as a solitary





























ietastases prior to conﬁrmation by imaging [13,22]. There are cur-
ently no diagnostic criteria for the detection of splenic metastasis
y imaging modalities. Although multi-modal imaging techniques,
ncluding CT [23], MRI  [24], and FDG-PET [24], have diagnostic util-
ty in such cases, the differentiation of a primary splenic tumor
rom lymphoma, vascular tumors, or infectious disorders can be
hallenging.
In this case, elevated serum SCC levels, CT imaging, abnor-
al  FDG accumulation on PET, and a history of gallbladder
arcinoma were all highly suggestive of splenic metastasis.
hough chemotherapy was initiated immediately after the initial
urgery, liver metastasis developed two months later. Splenec-
omy with partial liver resection was performed at this time.
athological examination of the surgical specimen demonstrated
denosquamous carcinoma with morphology resembling the
rimary gallbladder carcinoma conﬁrming our initial clinical diag-
osis.
Although splenectomy provides a potential means of radical
reatment in patients with isolated splenic metastases, it should
e performed with caution as splenic metastatic lesions may  rep-
esent the initial clinical manifestation of systemic metastases at
ultiple sites [9]. Under such circumstances, surgical stress from
plenectomy may  cause severe adverse clinical effects. Accord-
ngly, following the discovery of the splenic lesion, two cycles of
hemotherapy were administered in this case, rather than imme-
iate splenectomy, which also allowed for an observational period.
adical surgery was performed following the subsequent conﬁr-
ation of no new unresectable metastatic lesions or systemic
issemination. A Widely understood complication of splenectomy
s the asplenic patient’s susceptibility to infection [25], particu-larly to the pathogens, such as Streptococcus pneumoniae, Neisseria
meningitidis, and Haemophilus inﬂuenzae.  Prophylactic vaccinations
against these bacteria should ideally be given to patients about 2
weeks before the planned surgery or roughly 2 weeks after the
surgery. Furthermore, intraperitoneal hemorrhage is a fatal com-
plication of splenectomy [26,27]. Some medical conditions, such as
use of anticoagulant agents to prevent thrombosis and pancreatic
injury during surgery, have been identiﬁed and might be one of the
risk factors leading to hemorrhage after splenectomy [28].
Previous studies have reported long-term remission following
the detection of isolated splenic metastasis indicating this ﬁnd-
ing may  not necessarily be a sign of widespread, terminal cancer
[9–14,29]. Although the clinical course of splenic metastasis is
challenging to predict, surgical resection may  offer a feasible treat-
ment option. As an alternative treatment, chemotherapy might be
indicated for patients who had a relapse after surgery; however,
no standard treatment with solid evidence of a survival beneﬁt
has yet been established for such patients. Gemcitabine plus cis-
platin has become an established standard therapeutic regimen for
advanced biliary cancer [30,31]. New therapeutic modalities, such
as molecular-targeted therapies have recently been used for unre-
sectable disease, and randomized controlled trials are under way
to establish standard adjuvant chemotherapy for the resectable
disease [32–34].
We were unable to identify any reports of the splenic metastasis
of GB carcinoma, or adenosquamous carcinoma of the gallblad-
der, in previous literature. Further accumulation of reports of this
rare condition are therefore required to determine the efﬁcacy of
splenectomy in increasing survival and to deﬁne the role postop-
erative chemotherapy.
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Fig. 3. Macroscopic view of the cut specimen reveal the splenic tumor.








Cig. 4. Histopathologically demonstrated the primary gallbladder adenosquamous 
epresentative histological images of (A) the primary gallbladder adenosquamous ca
onsistent with adenosquamous carcinoma.
. Conclusion
Splenic metastasis of GB carcinoma is an extremely rare ﬁnding
uring follow-up of GB carcinoma. Curative resection may  repre-
ent the treatment of choice for prolonging survival in patients with
plenic metastasis of GB carcinoma.onﬂict of interest
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